Phathom Pharmaceuticals’ $130 Million Public Offering of Common Stock

Latham & Watkins advises Phathom Pharmaceuticals in pricing of US$130 million public offering of common stock.Phathom Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Marco Zingaro

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here